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Central nervous system remyelination by oligodendrocyte progenitor cells (OPCs) ultimately fails in the majority of multiple
sclerosis (MS) lesions. Remyelination benefits from transient expression of factors that promote migration and proliferation of
OPCs, which may include fibronectin (Fn). Fn is present in demyelinated lesions in two major forms; plasma Fn (pFn), depos-
ited following blood-brain barrier disruption, and cellular Fn, synthesized by resident glial cells and containing alternatively
spliced domains EIIIA and EIIIB. Here, we investigated the distinctive roles that astrocyte-derived Fn (aFn) and pFn play in
remyelination. We used an inducible Cre-lox recombination strategy to selectively remove pFn, aFn or both from mice, and
examined the impact on remyelination of toxin-induced demyelinated lesions of spinal cord white matter. This approach
revealed that astrocytes are a major source of Fn in demyelinated lesions. Furthermore, following aFn conditional knockout,
the number of OPCs recruited to the demyelinated lesion decreased significantly, whereas OPC numbers were unaltered fol-
lowing pFn conditional knockout. However, remyelination completed normally following conditional knockout of aFn and pFn.
Both the EIIIA and EIIIB domains of aFn were expressed following demyelination, and in vitro assays demonstrated that the
EIIIA domain of aFn mediates proliferation of OPCs, but not migration. Therefore, although the EIIIA domain from aFn medi-
ates OPC proliferation, aFn is not essential for successful remyelination. Since previous findings indicated that astrocyte-
derived Fn aggregates in chronic MS lesions inhibit remyelination, aFn removal may benefit therapeutic strategies to promote
remyelination in MS.
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Introduction
Multiple sclerosis (MS) is a central nervous system (CNS)disease, of which inflammation, demyelination, and
axonal loss are the main pathological features. Regeneration
of myelin (remyelination) involves proliferation and migration
of activated oligodendrocyte progenitor cells (OPCs) to
demyelinated lesions, and their subsequent differentiation
into myelinating oligodendrocytes (Franklin and ffrench-
Constant, 2008; Zawadzka et al., 2010). The extent of
remyelination in MS is variable, but often is insufficient to
prevent chronic axonal loss (Franklin et al., 2012; Patrikios
et al., 2006). Promoting endogenous remyelination provides a
means to reduce axonal degeneration and thereby slow pro-
gression of clinical disability (Duncan et al., 2009; Franklin
et al., 2012).
Fibronectin (Fn) is an extracellular matrix (ECM) pro-
tein, that is essential for embryonic development (George
et al., 1993). In healthy adults, Fn is continuously produced
by hepatocytes and circulates in the plasma. Fn is absent
from the healthy CNS, but expressed following injury, which
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includes demyelination. Plasma Fn (pFn) leaks across a dis-
rupted blood-brain barrier (Satoh et al., 2009; Sobel and
Mitchell, 1989; van Horssen et al., 2005), and cellular Fn
(aFn) is primarily synthesized by astrocytes (Hibbits et al.,
2012; Stoffels et al., 2013a), but also by microglia/macro-
phages and endothelial cells (Stoffels et al., 2013a). In con-
trast to pFn, cellular Fn may contain alternatively spliced
domains, named EIIIA, EIIIB, and the V-region in rodents
(EDA, EDB, and IIICS, respectively, in humans; Paul et al.,
1986; Schwarzbauer et al., 1987). In vitro, pFn stimulates
migration and proliferation of OPCs at low growth factor lev-
els via av integrin receptors, the only integrin receptors for
Fn present on OPCs (Baron et al., 2002; Blaschuk et al.,
2000; Milner and ffrench-Constant, 1994; Milner et al.,
1996). The expression of both Fn and av integrins is transi-
ently increased in demyelinated lesions (Stoffels et al., 2013a;
Zhao et al., 2009). Therefore, Fn may contribute to remyeli-
nation by promoting OPC recruitment. However, at later
stages of oligodendrocyte maturation, removal of Fn is
required for remyelination to proceed to completion, since
Fn inhibits myelin sheet formation (Buttery and ffrench-
Constant, 1999; Maier et al., 2005; Siskova et al., 2006,
2009). In addition, Fn aggregates impair OPC differentiation
in vivo, and likely contribute to remyelination failure in MS
(Stoffels et al., 2013a).
Here, we explored the role of Fn in more depth by ask-
ing what distinctive roles the two Fn variants, pFn and
astrocyte-derived Fn (aFn), play in remyelination. Using an
inducible Cre-lox recombination strategy to selectively remove
pFn, aFn or both (Hirrlinger et al., 2006; Sakai et al., 2001)
in combination with a well-established model of CNS de-
and remyelination (Blakemore and Franklin, 2008), we found
that conditional knockout of aFn, but not pFn, reduced the
density of OPCs. In vitro analysis revealed that this was likely
mediated by the EIIIA domain, which mediates OPC prolif-
eration on aFn at sufficient growth factor levels. However,
although conditional knockout of aFn was associated with
reduced OPC numbers following demyelination, it was not
sufficient to affect the remyelination outcome. The transla-
tional implication of our data therefore is that elimination of
aFn may be amenable in MS to prevent the formation of
remyelination-inhibiting Fn aggregates. This will likely be
beneficial in promoting endogenous remyelination (Stoffels
et al., 2013a).
Materials and Methods
Mice
Mice were housed under standard conditions. All experiments were
performed in compliance with United Kingdom Home Office regu-
lations. Plasma Fn (pFn) inducible, conditional knockout mice
(hereafter referred to as pFncKO) were a kind gift from Dr. R.
F€assler, Max Planck Institute for Biochemistry, Martinsried, Ger-
many. Inducible, conditional knockout (hereafter referred to as
“conditional knockout”) of pFn was created as described (Sakai
et al., 2001). Briefly, floxed Fn mice were crossed with mice express-
ing Cre recombinase under the control of the polyinosinic-
polycitidic acid (poly I:C) responsive Mx promoter (Mx-Cre). On
Cre-mediated recombination at the loxP sites, the start codon, signal
sequence and the exon/intron border of exon 1 are removed from
the Fn gene to generate the null allele (Sakai et al., 2001). Cre-
mediated recombination was induced in hepatocytes from the 6-
week old mice carrying Mx-Cre by two intraperitoneal injections of
poly I:C (GE Healthcare, Amersham, UK) with a 48 h interval as
previously described (Sakai et al., 2001). Wild type (WT) control
mice received vehicle only (phosphate-buffered saline; PBS). Mice
were subjected to lysolecithin-induced demyelination at 2–3 weeks
following induction of the knockout.
Conditional knockout mice devoid of aFn (astrocyte Fn;
aFncKO) were created by crossing Fn floxed mice with mice express-
ing Cre recombinase driven by human glial fibrilary acid protein
(GFAP), with its nucleus translocation controlled by a modified
estrogen receptor (hGFAP-CreERT2; Hirrlinger et al., 2006). The
hGFAP-CreERT2 mice were a kind gift from Dr. F. Kirchhoff, Max
Planck Institute of Experimental Medicine, Goettingen, Germany.
To induce conditional knockout of Fn from astrocytes, tamoxifen
(100 mg/kg in corn oil, Sigma-Aldrich, Gillingham, UK) was
injected intraperitoneally daily for 5 consecutive days, starting from
10 days prior to demyelination (Hirrlinger et al., 2006; Leone et al.,
2003). The littermate WT control group was injected with corn oil.
Compound astrocyte and pFn conditional knockout
(a1 pFncKO) was achieved by breeding mice heterozygous for
MxCre and hGFAP-CreERT2, and homozygous for the floxed Fn
gene. The induction protocol for these mice was the combination of
that described for single conditional knockout strains above.
Lysolecithin-Induced Demyelination of the Spinal
Cord and Tissue Processing
Surgery and tissue processing were performed as described (Zhao
et al., 2006). Briefly, mice at about 9–10 weeks old were anaesthe-
tized with isoflurane, and spinal cord lesions were created by direct
injection of 1 mL 1% lysolecithin into the ventral funiculus through
a gap between two thoraco-lumbar vertebrae. In the conditional
knockout mice, lesions were induced 1–2 weeks after completing the
induction protocol. Blood samples were obtained for isolating
plasma from the tail at the time of lesion, and collected in citrate-
dextrose solution (Sigma-Aldrich, Dorset, UK), then stored at
280C until use.
At the designated time post lesion, mice were euthanized by
intraperitoneal injection of pentobarbital followed by appropriate
protocols of tissue processing. For immunohistochemistry and in situ
hybridization, mice were perfusion fixed with 4% phosphate-
buffered paraformaldehyde (PFA) solution via the left ventricle, after
which the dissected spinal cord containing the lesions was either
directly frozen at 280C for later RNA extractions, or treated with
20% sucrose in PBS overnight. Cords were embedded in OCT
(Thermo Fisher Raymond Lamb, Loughborough, UK), and cut in
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coronal sections at 12 mm thickness. These sections were mounted on
poly-L-lysine (PLL)-coated slides (Polysciences Europe GmbH Eppel-
heim, Germany) and stored at 280C until further use. For resin
embedding and semi-thin sectioning, mice were perfused with 4%
phosphate-buffered gluteraldehyde and subjected to a standard resin
embedding process (Zhao et al., 2006). Semi-thin sections of 1 mm
were cut and stained with alkaline toluidine blue. Ranking analysis on
semi-thin sections of remyelinated lesions was performed by two inde-
pendent, blinded researchers as described (Ibanez et al., 2004).
Glial Cell Cultures
Primary glial cell cultures were generated from 1 to 2 day old Wistar
rats (Harlan, the Netherlands) as previously described (Baron et al.,
2002; Bsibsi et al., 2012). Briefly, after 10–12 days in culture on
PLL (5 mg/mL, Sigma-Aldrich, St. Louis, MO) coated flasks, OPCs
and astrocytes were isolated via a shake-off procedure (McCarthy
and de Vellis, 1980). Contaminating microglia were removed by
shaking the flasks at 150 rpm for 1 h at 37C on an orbital shaker.
Subsequently, flasks were shaken at 240 rpm overnight at 37C.
Floating OPCs were further purified by differential adhesion. Then,
OPCs were cultured in defined Sato medium (Maier et al., 2005)
on appropriate cell culture plastics for the different assays (see
below). Purity of the OPC cultures was routinely assessed by immu-
nocytochemistry for Olig2 (1:1000; Millipore, Billerica, MA) and
cultures used were >97% pure.
To obtain astrocytes, a subsequent overnight shake off was per-
formed at 240 rpm and the remaining astrocyte monolayer was
removed by trypsin. Astrocytes were cultured in T162 flasks (Corn-
ing Costar, Lowell, MA) in DMEM (Life Technologies, Paisley, UK)
containing 10% fetal calf serum (FCS; Bodinco, Alkmaar, The
Netherlands) and antibiotic supplements (Life Technologies), and
passaged once before experimental use. Regular immunocytochemis-
try for glial fibrillary acidic protein (GFAP; Millipore; 1:500) was
performed to assure sufficient purity of the astrocyte cultures
(>97%).
Plasma and Astrocyte-Derived Fibronectin Coatings
To obtain aFn, astrocytes were cultured on 10 cm dishes (Corning)
for 48 h, followed by water-lysis at 37C. The remaining astroglial
matrix was scraped in sterile PBS containing Complete Mini prote-
ase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany),
followed by protein concentration determination with Bio-Rad DC
protein assay (Bio-Rad Laboratories, Hercules, CA) using bovine
serum albumin (BSA) as standard. Then, 8-well chamber-slides were
incubated with 8 mg pFn from serum (Sigma-Aldrich) or 8 mg astro-
glial matrix protein (“aFn”) per well in PBS for 3 h at 37C. Simi-
larly, both sides of membranes on transwell microchambers (Becton-
Dickinson Labware, Bedford, MA) were coated with 10 mg of pFn
or aFn per well, and 3.5 mg pFn or aFn was used per well of a 96-
wells plate. When indicated, Fn coatings were incubated with func-
tional blocking antibodies (2 mg/mL) for 1 h at 37C, followed by a
gentle wash with PBS and seeding of OPCs. Blocking antibodies
used were: mouse anti-Fn IST9 (directed against the EIIIA domain,
Abcam, Cambridge, UK) and mouse anti-Fn C6 (directed against
the EIIIB domain, Abcam). Notably, the aFn preparation also con-
tains other astroglial matrix proteins, such as laminin (Liesi et al.,
1983, 1984) and chondroitin sulphate proteoglycans (Lau et al.,
2012), but although these proteins may affect OPC adhesion, prolif-
eration and migration also (Hu et al., 2009; Lau et al., 2012; Milner
et al., 1996), EIIIA and EIIIB are exclusively present in aFn.
SDS-PAGE and Western Blotting
Equal amounts of plasma from pFncKO and a1 pFncKO mice and
their controls were mixed with standard SDS sample buffer, heated
for 10 min at 95C, and separated by electrophoresis on SDS-PAGE
gels (8%, Expedeon, Cambridge, UK) for 1 h at 150 V. Protein was
transferred to a PVDF membrane (Invitrogen, Paisly, UK) using a
wet blotting system (Expedeon, Cambridge, UK) and according
glycine-Tris-methanol buffer. After three washes with 0.1% Tween-
20 in PBS, membranes were blocked with 5% non-fat milk solution
and incubated with a rabbit anti-Fn antibody (Millipore, Watford,
UK; 1:10,000) in blocking buffer, overnight at 4C. Membranes
were washed, and incubated with HRP-conjugated anti-rabbit anti-
body (Roche, Lewes, UK; 1:1000) in washing buffer. Signals were
detected using enhanced chemiluminescence plus (ECL plus; GE
Healthcare, Amersham, UK) followed by exposure on suitable X-ray
film (Thermo Scientific, Rockford, IL). For detection of mouse IgG
as a control, membranes were washed and incubated with biotinyl-
ated donkey antimouse IgG antibody (Jackson ImmunoResearch
Laboratories, Newmarket, UK; 1:1000) for 1 h, after which the Vec-
tastain ABC Elite kit (Vector Laboraties, Peterborough, UK) was
used according to the manufacturer’s instructions, and signals were
developed as described above.
Immunochemistry
Frozen spinal cord sections were air dried for 1 h and immunohis-
tochemistry was performed as described (Stoffels et al., 2013a) using
antibodies against Fn (Millipore; 1:1000), Olig2 (Millipore, 1:1000;
R&D Systems, Abingdon, UK; 1:200), Sox2 (Santa Cruz Biotech-
nology Inc, Dallas, TX; 1:500), KI67 (Abcam; 1:1000), and Iba1
(Abcam; 1:500). Antigen retrieval was performed before immuno-
staining with Olig2, using target retrieval solution (DAKO, Ely, UK)
at 95C for 20 min. Immunochemistry on coated aFn was per-
formed as described (Stoffels et al., 2013a), using antibodies against
Fn (1:50), IST9 (1:50), and C6 (1:50). Secondary antibodies used
were appropriate Alexa FluorVC (488 or 594)-conjugated secondary
antibodies (Invitrogen; 1:500).
For immunohistochemistry using primary antibodies generated
in mice on mouse tissue, a modified protocol was used. This proto-
col was applied for primary antibodies against Nkx2.2 (Developmen-
tal Studies Hybridoma Bank, Iowa, IA; 1:100), CC1 (Millipore;
1:100) and Aldh1L1 (NeuroMab, Davis, CA; 1:100) and secondary
antibodies used were Alexa FluorVC 488-conjugated-anti IgG2b (for
Nkx2.2 and CC1) or -anti IgG1 (for Aldh1L1; Invitrogen; 1:400).
Sections were first permeabilized with 1% Triton-X-100 in 0.05 M
Tris-buffered saline (TBS) for 30 min. Then, sections were blocked
for 30 min in TBS with 10% normal goat serum (NGS) and 0.25%
Triton-X-100, followed by another blocking step for 1 h using
mouse-on-mouse Ig solution (Vector Laboratories) according to the
manufacturer’s instructions. Primary antibodies were appropriately
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diluted in TBS containing 2% NGS and 0.3% Triton-X-100, and
applied for 1 h. Secondary antibodies were appropriately diluted in
TBS with 1% NGS, 0.1% Triton-X-100 and DAPI (1 mg/mL), and
applied for 15 min, followed by a 10 min incubation in 0.1% Sudan
Black in 70% ethanol. All incubations were at room temperature.
After each step, sections were washed in 0.05 M TBS with 0.1%
Tween-20 (VWR, Lutterworth, UK) 3 times 2 min.
Images from immunohistochemistry with either protocol were
acquired using a Zeiss Observer A1 fluorescent microscope, and images
from immunochemistry on coatings were acquired using a Zeiss Axio-
skop 2 microscope with Leica Application Suite V3 software. For
counting cell numbers, in each animal 3 demyelinated lesion levels
were selected, spanning the centre of lesions, at 120 mm distance
from each other. The outline of each lesion was defined based on the
increase in DAPI cellularity inside the lesion using Zeiss Axovision 4.8
software, which corresponds to the demyelinated area as stained for
with Sudan Black (Stoffels et al., 2013a). The numbers of marker-
positive cells inside the lesions were manually counted three times and
averaged for each lesion. There were 4–5 mice per group. To allow for
quantitative comparison, sections were stained in parallel and image
acquisitions were performed on the same day using identical camera
settings. Individual Fn- and Iba1-immunereactive cells could not be
discerned reliably, hence these were quantified by measuring the optical
densities from immunofluorescence using FIJI software.
In Situ Hybridization
The DIG-labeled PLP probe was obtained as described (Chari et al.,
2006), using mouse PLP cDNA (a kind gift from I.R. Griffiths,
Glasgow, UK) that was cloned into the pGEM4 plasmid (Promega,
Southampton, UK). To obtain the Fn probe, a cDNA fragment was
generated by reverse transcription PCR, using total RNA isolated
from WT mouse liver and the following Fn primers: forward: 50-
CACCACCCAGAACTACGATG-30, reverse: 50-GGACACCATGCA
CAAACTTC-30. The cDNA was inserted into the pGEM4 plasmid
(Promega, Southampton, UK). For both the PLP and Fn probes,
antisense digoxygenin labeled cRNA probes (riboprobes) were then
synthesized with appropriate RNA polymerase using a digoxigenin
(DIG) RNA labeling kit (Roche, Lewes, UK). The size of the ribop-
robes was checked by agarose gel electrophoresis. In situ hybridiza-
tion was then performed on air dried spinal cord sections as
described previously (Chari et al., 2006).
Real-Time PCR
Total RNA was isolated from tissue homogenates using the RNeasy
Mini kit (Qiagen). Reverse transcription of 0.5 mg total RNA was
performed in the presence of oligo(dT)12–18 and dNTPs (Invitro-
gen) with SuperScript_II reverse transcriptase (Invitrogen) according
to the manufacturer’s instructions. Real-time qPCR was performed
using the Applied Biosystems 7900HT Real-Time PCR System.
Each reaction contained 5 ng cDNA, 10 pM primers (listed in Table
1) and ABsolute SYBR Green Rox mix (Thermo Scientific, Lands-
meer, NL). No-template controls were performed to ensure that
amplification was not a result of contamination with genomic DNA.
Gene expression levels were analyzed using the 22DDct method
(Livak, 2001), and relative expression to HPRT1 or GAPDH. Simi-
lar results were obtained for both housekeeping genes.
BrdU Incorporation Assay
OPCs were plated on 8-well Permanox chamber-slides (Nunc,
Naperville, IL), precoated with 5 mg/mL PLL followed by appropri-
ate aFn or pFn coatings (described above), at a density of 30,000
cells per well. OPCs were allowed to incorporate 5-bromo-2-
deoxyuridine (BrdU; 10 mM; Roche) for 24 h in the presence of 10
ng/mL PDGF-AA and 10 ng/mL FGF-2. Then, cells were fixed in
4% PFA for 20 min, and additionally fixed in 5% acetic acid in
ethanol for 20 min. BrdU was detected using reagents from the
BrdU labeling and Detection Kit I (Roche) according to the manu-
facturer’s instructions with the addition of the oligodendrocyte line-
age marker Olig2 (Abcam) and Alexa FluorVC 546-conjugated anti-
rabbit antibody, and visualization of nuclei with DAPI (1 mg/mL).
To compare the percentages of BrdU-incorporating cells between the
conditions, the numbers of double BrdU- and Olig2-positive cells
were counted relative to the Olig2-positive cells (at least 150 cells
per condition) from images captured with a Leica TCS SP8 Confo-
cal Laser Scanning Microscope.
Transwell Migration Assay
OPCs were seeded on pFn or aFn coated-polyethylene terephthalate
membranes of 8 mm pore size (Becton-Dickinson Labware) in 12-
well modified Boyden transwell microchambers at a density of
80,000 cells per insert. OPCs were allowed to migrate through the
membranes for 4 h using 10 ng/mL PDGF-AA as a chemoattractant
in the bottom of the well. Nonmigrating cells were removed from
the top compartment with a cotton swab. Remaining cells in the
TABLE 1: Primer Sequences for Real-Time qPCR
Sense Antisense
EIIIA-fibronectin GTTAGTGTCTATGCTCAGAACC TCCACATCAGTGAATGCCAG
EIIIB-fibronectin AAAGATGACAAGGAAAGTGCCC ATGGTGGAAGAGTTTAGCGG
Fibronectin GTGAAAGGGAACCAGCAGAG CTTGAAGCCAATCCTTGGAG
HPRT1 GACTTGCTCGAGATGTCA TGTAATCCAGCAGGTCAG
GAPDH CATCAAGAAGGTGGTGAAGC ACCACCCTGTTGCTGTAG
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membranes were fixed for 20 min in 5% acetic acid in ethanol and
nuclei were visualized using DAPI (1 mg/mL) in PBS for 30 min.
After washing in PBS, membranes were mounted on glass slides and
images of DAPI-positive, migrated cells were captured using a Zeiss
Axioskop 2 plus microscope with Leica Application Suite v3 software
(15 3 20 fields per membrane). The numbers of cells were assessed
using FIJI software.
Adhesion Assay
pFn or aFn coated 96-wells plates (Nunc) were blocked for 30 min
with 1% heat-inactivated BSA at 37C. Then, wells were left
untreated or treated with the Fn blocking antibodies against EIIIA
or EIIIB (mouse anti-Fn IST9; Abcam and anti-Fn C6; Abcam).
After washing, 10,000 OPCs in 50 mL Sato medium per well were
allowed to adhere for 1 h at 37C. For integrin blocking experi-
ments, OPCs were preincubated with anti-integrin b1 (Becton Dick-
inson Pharmingen, Breda, NL; 1:200), anti-integrin b3 (Becton
Dickinson Pharmingen; 1:200) or anti-integrin b5 (Millipore,
Chemicon, Temecula, CA; 1:200) antibodies for 30 min at 37C.
The cells were washed two times with PBS, and adhered cells were
fixed for 15 min with ice-cold methanol. Cells were stained with
0.2% crystal violet (in 2% ethanol; Sigma), then washed several
times with water, after which the stain was solubilized in 1% SDS.
Adhesion was quantified by measuring the absorbance at 570 nm
after 30 min. In each independent experiment, adhesion is expressed
as percentage of the corresponding untreated substrate control result-
ing from triplicate determinations.
Statistical Analyses
Statistical analyses were performed in GraphPad Prism (GraphPad,
La Jolle, CA). First, the Kolmogorov-Smirnov test was applied to
test for a normal distribution of the data. Multiple group compari-
sons of data, which could thus be assumed to have a normal distri-
bution (data sets of FncKO mice, derived from
immunohistochemistry and in situ hybridization experiments, except
for the data describing immunofluorescence intensity of Fn- and
Iba1-staining), were performed using one-way ANOVA followed by
Tukey’s Multiple Comparison Test (* P< 0.05; ** P< 0.01; ***
P< 0.001). Multiple group comparisons of data that were not com-
patible with a normal distribution (data sets derived from in vitro
assays and real-time qPCR on demyelinated tissue, as well as of the
data describing immunofluorescence intensity of Fn and Iba1 stain-
ings) were performed using the Kruskal-Wallis test followed by
Dunn’s Multiple Comparison Test (*P< 0.05; ** P< 0.01; ***
P< 0.001). Nonparametric ranking data, derived from blindly rank-
ing alkaline toluidine blue stained resin sections for estimated
degrees of remyelination, were statistically analyzed using the Mann-
Whitney test (Ibanez et al., 2004). For the in vivo mice data from
immunohistochemistry, in situ hybridization and real time qPCR
studies, a representative graph of 2–3 independent experiments is
shown, displaying absolute means of 3–4 mice per group and 3
lesions levels per animal, each 120 mm from each other, with the
exception of immunochemistry for Iba1, data of which are shown as
a relative to the mean immunofluorescence levels of littermate WT
controls, set at 100% for each independent experiment. Quantifica-
tion methods are described under “immunochemistry.” For in vitro
proliferation, migration, and adhesion assays, graphs display mean
values relative to a control condition (aFn or pFn) from 3 to 5 inde-
pendent experiments. All error bars represent standard deviations.
Results
Fibronectin in Demyelinated Lesions is
Predominantly Produced by Astrocytes
Transient Fn expression during demyelination is hypothesized
to benefit remyelination (Hibbits et al., 2012; Stoffels et al.,
2013a; Zhao et al., 2009). The aim of the present study was
therefore to better define the potential involvement and
underlying mechanism(s) of the different Fn sources in
remyelination. We used a well-established rodent model of
experimental demyelination, in which focal, primary demye-
lination is created by the injection of lysolecithin into the
white matter of the spinal cord ventral funiculus (Blakemore
and Franklin, 2008). Spontaneous and complete remyelina-
tion of these lesions proceeds over a period of 21–28 days
in young adult rodents, which involves proliferation and
migration of local, activated OPCs to the demyelinated
lesions [“recruitment”; 1–10 days post lesion (DPL)], fol-
lowed by differentiation of oligodendrocytes and myelin
sheath formation (10–21 DPL) (Zhao et al., 2006). To elimi-
nate pFn and cellular Fn from lysolecithin-demyelinated
lesions, we used Cre/lox technology, creating conditional
knockout adult mice devoid of plasma Fn (pFncKO), astrocyte
Fn (aFncKO) or both (a1 pFncKO). The pFn null allele was
generated by activation of the Mx-Cre promoter with poly
I:C as described (Sakai et al., 2001), which removes the start
codon, signal sequence and the exon/intron border of exon 1
from the pFn gene. To remove cellular Fn, we targeted astro-
cytes, because they are considered a major source of Fn in the
CNS following injury (Hibbits et al., 2012), and synthesize
pathological Fn aggregates in MS (Stoffels et al., 2013a). We
thus used mice expressing Cre recombinase under control of
a GFAP promoter, which was rendered active by exposure to
tamoxifen via a modified estrogen receptor. The induction
efficiency was tested in a reporter line, as described in a previ-
ous report (Hirrlinger et al., 2006). In our own experiments,
this approach showed that at 5 days after a course of tamoxi-
fen administration in unlesioned adult mice, of astrocytes in
spinal cord white matter on average 78.5%6 2.4% SD
(n5 4) expressed the reporter (yellow fluorescent protein),
indicating an efficient recombination.
Using this approach, pFn was successfully eliminated
from plasma in pFncKO mice, as revealed by Western blot
analysis (Fig. 1A). Similar results were obtained on plasma
from a1 pFncKO mice, whereas pFn remained present in the
plasma of aFncKO mice as expected (Fig. 1B). Given the vir-
tual absence of aFn from the healthy CNS and its increased
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expression after demyelination (Stoffels et al., 2013a; Zhao
et al., 2009), we assessed local Fn expression in aFncKO and
a1 pFncKO mice after lysolecithin-induced demyelination of
the spinal cord ventral funiculus white matter (Fig. 1C). First,
we confirmed that astrocytes are a source of cellular Fn in
mouse demyelinated lesions, using immunhistochemistry
against GFAP and in situ hybridization for Fn mRNA on WT
lesions (Fig. 1D). Further, as shown in Fig. 1E,F, Fn expression
was increased in demyelinated lesions of littermate WTmice at
5 DPL, as previously reported for rat models (Stoffels et al.,
2013a; Zhao et al., 2009). Moreover, this increase was tran-
sient, and Fn levels were decreased in mice at 14 DPL (cf
Fig. 5, data not shown), similar to the transient expression pat-
tern of Fn observed in rats (Stoffels et al., 2013a; Zhao et al.,
2009). In pFncKO mice, Fn immunostaining was unaltered
compared with expression in littermate WT mice (Fig. 1E,F),
despite the strong reduction in Fn plasma levels (Fig. 1A).
These data indicate that either pFn is not a major source of Fn
expression within lysolecithin-induced lesions, or that aFn
expression may compensate for the loss of pFn. In contrast, Fn
expression was markedly reduced in demyelinated lesions of
aFncKO and a1 pFncKO mice (Fig. 1E,F), corroborating that
astrocytes are a major source of cellular Fn after demyelination.
Having reduced Fn levels from plasma and astrocytes, we next
analyzed how remyelination was affected at both the recruit-
ment and differentiation stages of remyelination.
FIGURE 1: Fibronectin expression is decreased in plasma and demyelinated whitematter of plasma, astrocyte, and astrocyte1plasma fibronec-
tin conditional knockout mice.A and B: Western blot analysis for fibronectin (Fn) and immunoglobulin M (IgM) on plasma of littermate wild type
(WT)mice and after conditional knockout of Fn from plasma (pFncKO), astrocytes (aFncKO) or astrocytes, and plasma (a1pFncKO). Note the virtual
absence of Fn from plasma after pFncKO and a1pFncKO. C: Demyelination was induced by injection of lysolecithin into the white matter of the
spinal cord ventral funiculus (red area).D: Immunohistochemistry for DAPI (cell nuclei) and GFAP (astrocytes) combined with in situ hybridization
for Fn mRNA on lysolecithin-demyelinated lesions of WT mice at 5 DPL, showing that Fn mRNA is present in astrocytes. E: Immunohistochemis-
try for Fn on lysolecithin-demyelinated lesions at 5 DPL after pFncKO, aFncKO, a1pFncKO, or in WT mice. F: Quantification of immunofluorescent
staining intensities in (E) from 3mice per group, and 3 lesion levels per animal, ~120 lmdistant from each other from images that were taken on
the same day using the exact same camera settings. Note the reduction in intensity of immunofluorescence relative to WT after aFncKO and
a1pFncKO, but not following pFncKO. Bars represent means. Error bars show standard deviations. Statistical analysis was performed using the
Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test (* P<0.05; ** P<0.01; *** P<0.001). Demyelinated lesion outlines were meas-
ured in Zeiss Axovision 4.8 software based on the increase in DAPI staining inside the lesions, and outlines are represented by dashed white
lines. Scale bar is 20 lm (D) and 50 lm (E). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Proliferation of OPCs in Response to Demyelination
is Decreased in Astrocyte Fibronectin Conditional
Knockout Mice
To determine whether the density of OPCs in the demyeli-
nated area is affected by pFncKO and/or aFncKO, we analyzed
OPC numbers after lysolecithin-induced demyelination in the
different FncKO mice. Immunostaining for Olig2 was used as
a marker for oligodendrocyte lineage cells (Arnett et al.,
2004; Fancy et al., 2009) and Sox2 and Olig2 double immu-
nohistochemistry to identify OPCs (Kondo and Raff, 2004;
Shen et al., 2008; Fig. 2A–D). This approach revealed a
small, significant reduction in Olig2-positive (Olig21) cells
and Sox21Olig21 cells after aFncKO, but not pFncKO at 5
DPL (Fig. 2A–D). A similar reduction in Olig21 and
Sox21Olig21 cells was detected after a1pFncKO (Fig. 2A–
D), indicating that the decrease in OPC density was associ-
ated with the decrease in aFn. An additional decrease in pFn
levels in a1 pFncKO did not further reduce the number of
OPCs. In support of these observations, by determining OPC
density using the transcription factor Nkx2.2 as a marker
(Watanabe et al., 2004), we similarly detected that the OPC
density was reduced after aFncKO and a1 pFncKO (Fig.
2E,F). The lesions were of comparable sizes in the different
FncKO samples relative to WT (data not shown). In tissue
culture, pFn promotes OPC migration and proliferation
(Baron et al., 2002; Hu et al., 2009; Milner et al., 1996). To
examine whether the reduction in OPC numbers in aFncKO
mice reflected an impairment in proliferation, we next ana-
lyzed the numbers of proliferating OPCs at 5 DPL, deter-
mined by co-labeling with Olig2 and the cell proliferation
marker KI67 (Gerdes et al., 1983). This revealed a reduction
in KI671Olig21 cells relative to Olig21 cells in aFncKO
and a1 pFncKO, but not pFncKO (Fig. 2G,H), indicating that
the decrease in OPC numbers is, at least partly, a result of
impaired proliferation. In contrast, we did not observe a sub-
stantial change in microglia/macrophage numbers after
FncKO, as assessed by immunohistochemistry for ionized
calcium-binding adaptor molecule 1 (Iba1) (Imai et al., 1996;
Fig. 3A,B). Similarly, astrocyte numbers were not significantly
affected by FncKO, as reflected by comparable numbers of
cells that stained positive for aldehyde dehydrogenase 1,
member L1 (Aldh1L1; Cahoy et al., 2008; Lovatt et al.,
2007; Fig. 3C,D). Hence, aFncKO resulted in a reduced num-
ber of OPCs after demyelination, whereas microglia/macro-
phage and astrocyte cell numbers were unaffected.
Oligodendrocyte Differentiation and Remyelination
are not Affected by Conditional Knockout of
Fibronectin from Astrocytes
We next examined whether the decreased OPC density
observed in aFncKO and a1 pFncKO during demyelination
resulted in altered CNS remyelination following lysolecithin-
induced demyelination. Oligodendrocyte lineage cell numbers
were analyzed by immunohistochemistry for Olig2 at 14 days
post lysolecithin-induced demyelination. As shown in Fig.
4A,B, Olig21 cells were still decreased in a1 pFncKO and
aFncKO as compared with littermate WT mice. In pFncKO
mice, Olig21 cell numbers did not differ from the WT mice
in the lesions. Furthermore, analysis of differentiated oligo-
dendrocytes, determined by immunohistochemical staining
for CC1 (Bhat et al., 1996), showed that the density of
CC11 cells was similar in all groups (Fig. 4C). This was
confirmed using an alternative marker of mature oligodendro-
cytes, in situ hybridization for proteolipid protein (PLP)
mRNA, a major myelin protein, which revealed no differen-
ces in PLP mRNA1 cells (Fig. 4D,E). Therefore, despite a
reduction of OPCs after demyelination in aFncKO and
a1 pFncKO, it was not sufficient to result in an impairment
of oligodendrocyte generation at 14 DPL.
To assess whether myelin sheath formation was affected,
we examined toluidine blue stained semithin resin sections of
lesions from littermate WT and a1 pFncKO mice at 21 DPL.
We could not detect any gross morphological differences
between remyelinated lesions from littermate WT and
a1 pFncKO mice (Fig. 4F). Ranking analysis of the degree of
remyelination (Ibanez et al., 2004) did not reveal significant
differences between WT and a1 pFncKO lesions either (Fig.
4G). Therefore, aFn, although involved in OPC recruitment,
is not essential for remyelination.
Expression of the Alternatively Spliced Domains
EIIIA and EIIIB mRNA of Cellular Fibronectin is
Increased Following Demyelination
We next investigated the specific contribution of the alterna-
tively spliced domains EIIIA and EIIIB, exclusively localized
within the cellular Fn structure (Paul et al., 1986; Schwarzba-
uer et al., 1987) in the regulation of OPC proliferation fol-
lowing demyelination. We first determined the expression of
both domains following demyelination of the mouse spinal
cord ventral funiculus by quantitative, real-time PCR analysis
of mRNA expression. Compared with unlesioned tissue,
EIIIA, EIIIB, and total Fn mRNA levels were increased in
demyelinated tissue at 5 DPL relative to expression of the
housekeeping gene GAPDH (Fig. 5A–C; 5 DPL), similar to
our previous report for total Fn protein and Fn EIIIA protein
(Stoffels et al., 2013a). Furthermore, during remyelination
(14 DPL), mRNA levels of EIIIA, EIIIB, and total Fn
returned to lower levels (Fig. 5A–C; 14 DPL). Because both
EIIIA and EIIIB mRNA levels are increased at 5 DPL, when
OPCs are recruited, and since these elements are exclusively
present in Fn derived from local cellular sources, such as
astrocytes, we next examined the extent to which aFn EIIIA,
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FIGURE 2: OPC numbers in lysolecithin-induced demyelinated lesions decrease after conditional knockout of astrocyte fibronectin, but not after
plasma fibronectin conditional knockout alone. A–I: After 5-days post lysolecithin-demyelinated lesions (5 DPL) of the mouse spinal cord ventral
funiculus, the density of Olig2-positive (“Olig21”; A,B), Sox21 Olig21 (C,D), Nkx2.21 (E,F), and KI671Olig21 (G,H) cells were determined by
immunohistochemistry. Note the decrease in Olig21, Sox21Olig21, Nkx2.21, and KI671Olig21 cells number after conditional knockout of
fibronectin from astrocytes (aFncKO) or from astrocytes and plasma (a1pFncKO), but not from plasma alone (pFncKO) relative to littermate WT
mice. Images in A,C,E andG are representative images of demyelinated areas in the different groups. Insets showhigher powermagnifications of
thedouble positive cells thatwere counted,with the blue color representingDAPI staining. The outlineof the demyelinated lesionswasmeasured
in Zeiss Axovision 4.8 software based on increased DAPI stainings’ inside lesions and outlines are represented by dashed white lines. Double
(C,G) or single (A,E) positive cell numbers were manually counted 3 times for 4 mice per group, and 3 lesion levels per animal, ~120 lm distant
from each other. Representative graphs of 2–3 independent experiments are shown. Bars representmeans. Error bars show standard deviations.
Statistical analyses were performed using one-way ANOVA, followed by Tukey’s Multiple Comparison Test (* P<0.05; ** P<0.01; *** P<0.001;
NS: not significant). Scale bars are 50 lm. [Color figure canbe viewed in the online issue, which is available atwileyonlinelibrary.com.]
EIIIB, or both are involved in proliferation and/or migration
of OPCs in vitro.
The EIIIA Domain of Astrocyte-Derived Fibronectin
Mediates Proliferation of OPCs, but not Their
Migration and Adhesion
To examine the effect of pFn and aFn on OPC proliferation,
we used commercially available pFn from bovine plasma and
aFn derived from extracellular deposits of primary astrocytes
(Fig. 6A, “Fn”). The aFn preparation contained the alterna-
tively spliced domain EIIIA (Fig. 6A, “EIIIA”) and EIIIB (Fig.
6A, “EIIIB”), as confirmed by immunostaining with domain-
specific antibodies. Functional blocking antibodies against
EIIIA (“IST9”, Liao et al., 1999) and EIIIB (“C6”, Balza
et al., 2009) were used to eliminate signals from these
domains. OPCs were allowed to proliferate on the different
substrates in the presence of relatively high levels of PDGF-AA
and FGF-2 for 24 h, after which percentages of BrdU-
incorporating Olig21 cells were determined by immunocyto-
chemistry as a measure of OPC proliferation. As expected
under these conditions (Baron et al., 2002, Colognato et al.,
2004), OPCs proliferated equally well on either aFn (166 5%
SD) or pFn (156 8% SD; Fig. 6B), and to comparable levels
when grown on PLL (data not shown). However, proliferation
of OPCs was markedly reduced when the cells were cultured
on aFn with the EIIIA domain blocked (Fig. 6B;
“aFn1 IST9”). In contrast, addition of the EIIIA blocking
antibody to pFn did not affect OPC proliferation (Fig. 6B;
“pFn1 IST9”), indicating that the reduction in OPC prolifer-
ation following the blocking of EIIIA with the IST9 antibody
was attributable to the specific effect(s) of the antibody. More-
over, blocking EIIIB from aFn (Fig. 6A; “EIIIB”) with the C6
antibody (Fig. 6B; “aFn1C6”) did not affect OPC prolifera-
tion. To determine whether EIIIA and/or EIIIB of aFn are also
important for OPC migration, we allowed OPCs to migrate
through transwell microchambers, containing membranes
coated with pFn or aFn on both sides, using PDGF-AA as an
attractant in the bottom well. As shown in Fig. 6C, migration
FIGURE 3: Microglia and astrocyte cell numbers in lysolecithin-demyelinated lesions are not affected by conditional knockout of plasma
and/or astrocyte fibronectin. A–D: After 5 DPL of the mouse spinal cord ventral funiculus from littermate WT mice and after conditional
knockout of Fn from plasma (pFncKO), astrocytes (aFncKO), or astrocytes and plasma (a1pFncKO)., the density of Iba11 cells was determined
by measurement of relative immunofluorescence (A,B), and Aldh1L11 cells were stained by immunohistochemistry, then counted (C,D). Rep-
resentative images of demyelinated areas in the different groups are shown. Insets show higher power magnifications of the double positive
cells, with the blue color representing DAPI staining. The outline of the demyelinated lesions was measured in Zeiss Axovision 4.8 software
based on increased DAPI stainings’ inside lesions and outlines are represented by dashed white lines. Immunofluorescence levels of Iba1
cells were measured using FIJI software (A,B) and Aldh1L11 cell numbers were manually counted 3 times for 4 mice per group, and 3 lesion
levels per animal, ~120 lm distant from each other. Representative graphs of 2–3 independent experiments are shown. Bars represent
means. Error bars show standard deviations. Statistical analyses were performed using the Kruskal-Wallis test followed by Dunn’s Multiple
Comparison Test (A,B) or one-way ANOVA, followed by Tukey’s Multiple Comparison Test (C,D) (*P<0.05; ** P<0.01; *** P<0.001; NS: not
significant). Scale bars are 50 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIGURE 4: Oligodendrocyte differentiation and remyelination are not affected by conditional knockout of fibronectin from astrocytes.
A–E: At 14 days post lysolecithin-induced demyelination (14 DPL) of the spinal cord ventral funiculus, immunohistochemistry (A–C) and
in situ hybridization (D,E) were applied to determine the numbers of Olig21 (A,B), CC11 (C), and PLP mRNA1 (D,E) cells in littermate
WT mice or after conditional knockout of fibronectin from plasma (pFncKO), astrocytes (aFncKO), or astrocytes, and plasma (a1pFncKO).
Note the significant decrease of Olig21 oligodendrocyte lineage cells after aFncKO and a1pFncKO (A,B), whereas the numbers of differ-
entiating oligodendrocytes do not differ from littermate WT mice (C–E). Images in A and D are representative images of demyelinated
areas in the different groups. Insets show higher power magnifications of the positive cells that were counted, with the blue color repre-
senting DAPI staining. Outlines of demyelinated lesions were measured in Zeiss Axovision 4.8 software based on the increase in DAPI
staining inside lesions, and outlines are represented by dashed lines. Cell numbers were manually counted 3 times from 4 mice per
group, and 3 lesion levels per animal, ~120 lm distant from each other. Representative graphs of 2–3 independent experiments are
shown. Bars represent means of each group. Error bars show standard deviations. Statistical analyses were performed using one-way
ANOVA, followed by Tukey’s Multiple Comparison Test (** P<0.01; *** P<0.001; NS: not significant). Scale bars are 50 lm. F,G. At 21
DPL, semi-thin sections of resin-embedded WT and a1pFncKO mice were stained with alkaline toluidin blue to analyze the myelin struc-
ture (F), and blindly ranked according to estimated percentage of remyelination by two independent researchers, after which statistical
differences were analyzed using the Mann Whitney test (G). Scale bar is 100 lm. NS means “not significant.” [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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of OPCs was similar on aFn and pFn, and was not affected by
blocking the EIIIA or EIIIB domains. These experiments dem-
onstrate that EIIIA, but not EIIIB, is primarily required for
proliferation of OPCs on aFn, and that neither domain is
essential for migration of OPCs on aFn.
Proliferation of OPCs on pFn at low levels of PDGF-
AA is largely mediated by the integrin receptors avb3 and to
a lesser extent by avb1 (Baron et al., 2002; Blaschuk et al.,
2000; Milner et al., 1996). Although EIIIA does not directly
bind to avb1 or avb3, it has been reported that EIIIA may
indirectly promote adhesion of cellular Fn to these integrins,
thereby facilitating proliferation (Manabe et al., 1999). To
test this possibility, we assessed whether adhesion of OPCs to
aFn indirectly involved integrin b binding by using blocking
antibodies against integrins b1, b3 and b5, and whether such
adhesion was facilitated by functional EIIIA and EIIIB
domains. Compared with adhesion to pFn (Fig. 6D;
“pFn1b3” and “pFn1b5”), adhesion of OPCs to aFn was
only modestly reduced when the integrins b3 (Fig. 6E;
“aFn1b3”) and b5 (Fig. 6E; “aFn1b5”) were blocked. In
contrast, integrin b1 had no effect on adhesion of OPCs to
both pFn and aFn (Fig. 6D,E; “pFn1b1” and “aFn1b1”).
Furthermore, functional blocking of EIIIA and EIIIB
domains did not alter adhesion of OPCs to aFn (Fig. 6F).
Thus, whereas the integrin b3 and b5 receptors likely medi-
ate adhesion of OPCs to aFn, adhesion of OPCs does not
require functional EIIIA or EIIIB domains of aFn.
Discussion
In this study, we investigated how Fn, derived from plasma
(pFn) or cellular Fn derived from astrocytes (aFn), modulates
remyelination following CNS demyelination. After conditional
knockout of Fn from astrocytes (aFncKO) or both astrocytes
and plasma (a1 pFncKO), the density of (proliferating) OPCs
in demyelinated lesions was reduced. Our in vitro analyses of
OPCs, cultured on either pFn or aFn, revealed that the alter-
natively spliced EIIIA domain, exclusively present in cellular
Fn, is instrumental in proliferation. Our data further showed
that this control of proliferation by the EIIIA domain was
likely not related to an ability of EIIIA to enhance adhesion of
OPCs, although integrins b3 and b5 mediate adhesion of
OPCs to aFn. Furthermore, we did not observe an effect of
aFn on migration of OPCs. Despite a reduction in oligoden-
drocyte lineage cells on a1 pFncKO at later stages of the
remyelination process, both pFn and aFn were dispensable for
oligodendrocyte differentiation and complete remyelination.
Although both EIIIA and EIIIB are largely absent from
healthy tissue after embryonic development, reappearance of
cellular Fn with the alternatively spliced EIIIA and EIIIB
domains occurs after injury of different tissue types (ffrench-
Constant et al., 1989; Jarnagin et al., 1994; Nickeleit et al.,
1996; Ulrich et al., 1997). Injury-induced expression of cellu-
lar Fn containing EIIIA is associated with increased cell pro-
liferation, as demonstrated in a variety of cell types (Manabe
et al., 1999; Olsen et al., 2012; Stenzel et al., 2011). In addi-
tion, while proliferation of OPCs is known to be independent
FIGURE 5: Enhanced expression of fibronectin alternatively
spliced domains EIIIA and EIIIB mRNA after lysolecithin-induced
demyelination of the mouse spinal cord ventral funiculus. A–C:
Real-time PCR on spinal cord RNA from control mice (unle-
sioned), at 5 days (5 DPL) or 14 days (14 DPL) post lysolecithin-
induced demyelination. Note the increase in fibronectin EIIIA
and EIIIB mRNA at 5 DPL. Gene expression levels were analyzed
using the 22DDct method (Livak, 2001), with relative expression
to HPRT1 or GAPDH. Similar results were obtained for both
housekeeping genes; graphs shown the relative expression to
GAPDH. Statistical analysis was performed using the Kruskal-
Wallis Test, followed by Dunn’s Multiple Comparison Test
(* P<0.05; **<P 0.01).
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of pFn at sufficient levels of mitogenic growth factors (Baron
et al., 2002, Colognato et al., 2004), which are likely also
sufficient in lysolecithin-induced demyelinated lesions (Hinks
and Franklin, 1999), our data indicate that the EIIIA domain
is essential for proliferation of OPCs on aFn under these con-
ditions. This suggests that proliferation of OPCs on aFn
involves a different mechanism from pFn. The EIIIA could
theoretically mediate proliferation of OPCs on aFn via bind-
ing to the integrins a9b1 (Olsen et al., 2012; Ou et al.,
2013; Sun et al., 2014) and a4b1 (Liao et al., 2002), or by
enhancing the binding affinity of other integrin receptors for
Fn, most notably a5b1 and avb3 (Manabe et al., 1997,
1999; Xia and Culp, 1995). However, integrins a4b1 and
a9b1 are not expressed by OPCs (Milner and ffrench-
Constant, 1994) and the EIIIA domain was not important
for adhesion of OPCs to aFn, implying that EIIIA mediates
FIGURE 6: Blocking the EIIIA domain from astrocyte-derived fibronectin affects OPC proliferation, but not migration and adhesion. A: Astro-
glial matrix derived from neonatal rat astrocytes (aFn) immunostained for total fibronectin (“Fn”), and the alternatively spliced EIIIA (“EIIIA”)
or EIIIB (“EIIIB”) domains. Scale bar is 50 lM. B: OPCs from neonatal rats were cultured for 24 h on plasma fibronectin (pFn) or aFn, alone or
in the presence of blocking antibodies against the EIIIA or EIIIB domain and subjected to a BrdU incorporation assay combined with Olig2
immuncytochemistry. On aFn, 16% of OPCs proliferated on average65% SD. Note that addition of an EIIIA blocking antibody (“aFn1 IST9”)
decreased the number of Olig21 OPCs incorporating BrdU on aFn, but not on pFn (“pFn1 IST9”), and BrdU incorporation did not differ
between the other conditions. C: OPCs were allowed to migrate through transwell inserts coated with aFn or pFn for 4 h, alone or in the pres-
ence of blocking antibodies against EIIIA (“pFn1 IST9”; “aFn1 IST9”) or EIIIB (“aFn1C6”) antibodies. Note that the numbers of migrated
cells did not differ between the conditions. D–F: OPCs were allowed to adhere to pFn (D) or aFn (E,F) in the presence of blocking antibodies
against integrins b1 (“pFn1 b1,” “aFn1 b1”), b3 (“pFn1 b3,” “aFn1 b3”), or b5 (“pFn1 b5, “aFn1 b5”; D,E) or after blocking the EIIIA
(“aFn1 IST9”) or EIIIB (“aFn1C6”; F) domains of aFn. Note that whereas integrins b3 and b5 likely mediate adhesion of OPCs, particularly to
aFn (E), adhesion does not require a functional EIIIA or EIIIB domain on aFn (F). Bars in the graphs represent means of 3–4 independent
experiments. The horizontal, dashed line represents pFn (D) or aFn-treated (B, C, E, F) cells, and this condition was set to 100% in each experi-
ment. Error bars show standard deviations. Statistical analyses were performed using the Kruskal-Wallis Test, followed by Dunn’s Multiple
Comparison Test (** P<0.01; NS: not significant). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Stoffels et al.: Astrocyte-Derived Fibronectin and OPC Proliferation
February 2015 253
proliferation of OPCs through an alternative mechanism.
This mechanism may involve other domains of Fn, since
alternative splicing of Fn can change the conformation of Fn,
affecting the presentation of binding sequences and exposing
cryptic binding sites (Pickford and Campbell, 2004; Ventura
et al., 2010). In addition to EIIIA, expression of the EIIIB
domain was also upregulated after demyelination. Whereas
EIIIB appears not to have a role in proliferation and migra-
tion of OPCs, its functional involvement in processes other
than proliferation and migration cannot be excluded and
merits further investigation.
The apparent redundancy of pFn for achieving a normal
cell density of OPCs observed in our in vivo studies was unex-
pected, given that stimulation of cell proliferation and migra-
tion by pFn is well documented for several cell types (To and
Midwood, 2011; von Au et al., 2013), including OPCs at low
growth factor levels (Baron et al., 2002; Colognato et al., 2004;
Hu et al., 2009; Milner et al., 1996). Our in vitro proliferation
studies suggested that OPCs proliferate equally on pFn and aFn
in the presence of PDGF-AA and FGF-2. After pFncKO, a
compensatory increase in cellular Fn may have occurred, medi-
ated by astrocytes, microglia/macrophages, and endothelial cells
(Stoffels et al., 2013a). From these cell types, astrocytes are
thought to represent the major source of Fn after toxin-induced
demyelination (Hibbits et al., 2012; Stoffels et al., 2013a),
which is further supported in this study, given the pronounced
reduction in Fn levels after aFncKO. Therefore, a compensatory
increase in aFn could explain the absence of a clear phenotype
after pFncKO, in agreement with studies of other tissues (Sakai
et al., 2001). However, the observation that a1 pFncKO does
not substantially amplify the reduction in OPC numbers during
demyelination may support an alternative explanation, namely
that excessive leakage of pFn to the demyelinated area does not
occur on lysolecithin-induced demyelination, despite breakdown
of the blood-brain barrier (Ford et al., 1990). Hence, in con-
trast to previous studies, in which pFn was considered a pre-
dominant source of the Fn matrix in tissue (Moretti et al.,
2007), our findings indicate that aFn rather than pFn is the
major component of the Fn matrix expressed after lysolecithin-
induced CNS demyelination. In MS lesions, where immune-
mediated blood-brain barrier disruption is more diffuse, pFn
may be a more prominent source of Fn. Also, pFn could
potentially modulate OPC proliferation when growth factor lev-
els are low (Baron et al., 2002; Colognato et al., 2004).
Although aFn mediates OPC cell numbers in demyeli-
nated lesions, it is dispensable for remyelination. Moreover, at
the stage of oligodendrocyte differentiation, the absolute
numbers of differentiated oligodendrocytes did not differ
between aFncKO or a1 pFncKO and WT animals. After
lysolecithin-induced demyelination in WT animals, the
amount of differentiating oligodendrocytes remains relatively
stable from this stage onwards until the completion of remye-
lination (Fancy et al., 2004; our unpublished observations).
This indicates that despite the reduced numbers of OPCs
after aFncKO or a1 pFncKO, sufficient numbers of differenti-
ated oligodendrocytes are still generated to reach the maximal
level of differentiation necessary to remyelinate the lesion. In
this way, relative redundancy of aFn, in spite of decreased
OPC proliferation after aFncKO, is consistent with the con-
cept that OPCs are normally recruited in excess relative to
the numbers required for remyelination following small, focal,
toxin-induced lesions (Franklin and ffrench-Constant, 2008;
Stidworthy et al., 2004). In addition, functional compensa-
tion may result from the increased expression of several other
ECM proteins in demyelinated lesions (Zhao et al., 2009). In
support of this, osteopontin, another ECM molecule
expressed after demyelination, is also redundant for remyeli-
nation (Zhao et al., 2008). In contrast to modulation of
OPC proliferation by aFn, which likely promotes recovery,
persistent expression of Fn variants in pathology mediates fail-
ure of tissue regeneration (Stoffels et al., 2013b). In particu-
lar, the EIIIA domain is involved in adverse remodeling after
tissue injury (Arslan et al., 2011; Hirshoren et al., 2013;
Kohan et al., 2010; Muro et al., 2008). In MS lesions, Fn
assembles into aggregates, which is likely mediated by inflam-
matory factors. Astrocytes are an important source of Fn
aggregates, and these Fn aggregates contribute to remyelina-
tion failure (Stoffels et al., 2013a). Since our findings indicate
that aFn is a nonessential element for remyelination, develop-
ing therapeutic approaches that remove aggregates of Fn from
MS lesions represent a legitimate translational objective.
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